Related Experiment Video
Updated: Feb 10, 2026

Place and Response Learning in the Open-field Tower Maze
Published on: October 28, 2015
Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study
Mark S Freedman1, Julia Morawski2, Karthinathan Thangavelu3
1Multiple Sclerosis Research Clinic, University of Ottawa and the Ottawa Hospital Research Institute, Canada.
Abstract:
Patients enrolled in the phase 3 TOWER study (NCT00751881) of teriflunomide had variable treatment durations (48-173 weeks). This has led to challenges when interpreting results in the context of other phase 3 trials of disease-modifying therapies for multiple sclerosis, which typically have a fixed 2-year duration. This communication reports clinical outcomes in TOWER over a fixed 2-year period. Reductions in annualised relapse rates and 12-week confirmed disability worsening associated with teriflunomide were comparable between overall intent-to-treat and fixed 2-year study populations in TOWER. Consistency in outcomes supports the inclusion of TOWER data in comparative analyses with other disease-modifying therapies. ClinicalTrials.gov: NCT00751881.
More Related Videos
05:00Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms
Published on: March 3, 2021
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Self-Efficacy
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Fixed Action Patterns
Hypertension III: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Fixing Double-strand Breaks